• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alkermes plc

    4/6/26 5:11:54 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    DEFA14A 1 alks_defa14a_2026_notice.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No. )

     

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant o

    Check the appropriate box:

    o

    Preliminary Proxy Statement

    o

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    o

    Definitive Proxy Statement

    x

    Definitive Additional Materials

    o

    Soliciting Material under §240.14a-12

    ALKERMES PLC

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    x

    No fee required.

    o

    Fee paid previously with preliminary materials.

    o

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


     

    img77628588_0.jpg

     

    C/O BETANXT, INC. P.O. BOX 8016, CARY, NC 27512-9903 Your vote Alkermes plc 2026 Annual General Meeting of Shareholders Wednesday, May 20, 2026, 2:00 PM, Irish Standard Time Alkermes plc offices, located at Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6 Meeting Materials: Notice of Meeting and Proxy Statement; Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held on May 20, 2026 for Shareholders as of March 13, 2026 To request paper materials, please use one of the following methods: For a convenient way to view Alkermes plc's proxy materials, and VOTE your shares, please visit www.proxydocs.com/ALKS. To vote while visiting this site, you will need the 12 digit control number in the box below. You may vote your proxy by Internet or telephone prior to 11:59 PM Eastern Standard Time on May 19, 2026 (4:59 AM Irish Standard Time on May 20, 2026). This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this Notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under U.S. Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper copy. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper copy in time for the Alkermes plc (the "Company") 2026 annual general meeting of shareholders (the "Annual Meeting"), you must make this request on or before May 8, 2026. SEE REVERSE FOR PROXY PROPOSALS Internet: www.investorelections.com/ALKS Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting receipt of proxy materials, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting proxy materials. Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img77628588_1.jpg

     

    Alkermes plc 2026 Annual General Meeting of Shareholders THE BOARD OF DIRECTORS OF THE COMPANY (THE "BOARD") RECOMMENDS A VOTE: FOR ALL DIRECTOR NOMINEES NAMED IN PROPOSAL 1 FOR PROPOSALS 2, 3, 4, 5 AND 6 PROPOSAL 1. To elect as directors to serve a one-year term until the Company's 2027 annual general meeting of shareholders: 1.01 Shane M. Cooke 1.02 Richard B. Gaynor, M.D. 1.03 Cato T. Laurencin, M.D., Ph.D. 1.04 Nancy S. Lurker 1.05 Brian P. McKeon 1.06 Richard F. Pops 1.07 Nancy L. Snyderman, M.D. 1.08 Frank Anders Wilson 1.09 Christopher I. Wright, M.D., Ph.D. 2. To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. 3. To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration. 4. To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. 5. To renew Board authority to allot and issue shares under Irish law. 6. To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law. If any other matter is presented at the Annual Meeting upon which a vote may be properly taken, ordinary shares represented by all proxy cards received by the Company will be voted at the discretion of the named proxy holders as set forth on the proxy card. Any shareholder entitled to attend, speak and vote at the Annual Meeting may appoint one or more proxies, who need not be a shareholder of record of the Company. If you wish to appoint as proxy any person other than the individuals specified on the Company's proxy card, you may do so by contacting the Company Secretary at Alkermes plc, Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6, Attention: Company Secretary, or by delivering to the Company Secretary a proxy card in the form mailed to you or in the form set forth in Section 184 of the Irish Companies Act 2014. To obtain directions to attend the Annual Meeting, please contact the Company's Investor Relations team at investor_relations@alkermes.com. The Company's Irish statutory financial statements for the year ended December 31, 2025, including the reports of the directors and auditors thereon, are available on the Annual Reports page of the Investors section of the Company s website at http://investor.alkermes.com. If you wish to receive a paper or e-mail copy, please contact the Company Secretary using the contact information above.


    Get the next $ALKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    7/13/2026$60.00Neutral
    Analyst
    6/29/2026$38.00Neutral → Underperform
    BofA Securities
    2/24/2026$45.00Outperform
    Wolfe Research
    11/11/2025$50.00Buy
    Truist
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    More analyst ratings

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $109,897 worth of Ordinary Shares (2,034 units at $54.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.89% to 227,490 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    7/6/26 4:48:01 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP R&D, Chief Medical Officer Hopkinson Craig C. sold $463,621 worth of Ordinary Shares (9,000 units at $51.51) as part of a pre-agreed trading plan and exercised 5,000 units of Ordinary Shares at a strike of $19.34, decreasing direct ownership by 5% to 73,389 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    7/1/26 6:29:17 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wright Christopher I sold $90,200 worth of Ordinary Shares (2,000 units at $45.10) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 25,680 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    6/12/26 8:04:20 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global

    7/14/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    — First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2 — — Improvements in Patient-Reported Cognition and Fatigue Were Also Sustained — — Alixorexton Was Generally Well Tolerated at All Doses Tested — Alkermes plc (NASDAQ:ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meani

    7/13/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    — First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Narcolepsy Type 2 — — Improvements in Wakefulness and Patient-Reported Cognition and Fatigue Were Sustained Through 13 Weeks — — Alixorexton Was Generally Well Tolerated at All Doses Tested — Alkermes plc (NASDAQ:ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study's dual primary endpoints, demonstrating statistically significant and cl

    6/17/26 4:15:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on Alkermes Plc with a new price target

    Analyst resumed coverage of Alkermes Plc with a rating of Neutral and set a new price target of $60.00

    7/13/26 9:06:24 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc downgraded by BofA Securities with a new price target

    BofA Securities downgraded Alkermes Plc from Neutral to Underperform and set a new price target of $38.00

    6/29/26 8:53:48 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Alkermes Plc with a new price target

    Wolfe Research initiated coverage of Alkermes Plc with a rating of Outperform and set a new price target of $45.00

    2/24/26 7:45:07 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    Alkermes plc filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Alkermes plc. (0001520262) (Filer)

    7/8/26 8:00:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    6/15/26 7:09:44 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    5/20/26 4:10:47 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global

    7/14/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Reports First Quarter 2026 Financial Results

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1

    5/5/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report First Quarter Financial Results on May 5, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global bio

    4/21/26 4:05:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes plc Announces CEO Succession Plan

    — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors — Alkermes plc (NASDAQ:ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1,

    2/25/26 6:55:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care